A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04464187|
Recruitment Status : Recruiting
First Posted : July 9, 2020
Last Update Posted : November 10, 2022
Orilissa is a drug approved for the management of moderate to severe pain associated with endometriosis. Oriahnn is approved for heavy menstrual bleeding due to uterine fibroids. Elagolix-containing products should not be taken by women who are pregnant or suspected to be pregnant but pregnancies are expected as the medicine does not completely stop ovulation and women may inadvertently continue taking Elagolix-containing products until their pregnancy is confirmed.
This study will assess pregnancy outcomes (maternal, fetal, and infant) of participants with and without exposure to Elagolix-containing products for their endometriosis or other conditions based on approved indications and prescribing patterns of Elagolix. Around 584 participants will be enrolled (292 participants exposed to Elagolix and 292 without exposure) in the United States.
Participants will not receive Elagolix-containing products as part of this study but will be followed for maternal and fetal outcomes up to 1 year after delivery.
There may be a higher burden for participants in this study compared to standard of care. Participants will be asked to provide additional information by questionnaire during each trimester of pregnancy, and at 0-6 weeks, 26 weeks, and 1 year after delivery.
|Condition or disease|
|Endometriosis Uterine Fibrioids|
|Study Type :||Observational|
|Estimated Enrollment :||584 participants|
|Official Title:||Prospective Registry to Evaluate Pregnancy Outcomes in Women Treated With Elagolix|
|Actual Study Start Date :||January 6, 2022|
|Estimated Primary Completion Date :||January 16, 2029|
|Estimated Study Completion Date :||January 23, 2029|
Participants exposed to Elagolix-containing products
Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
Participants not exposed to Elagolix-containing products
Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
- Rate of major congenital malformations [ Time Frame: Approximately 2 years (1 year post-delivery) ]Defined as an abnormality in structural development that is medically or cosmetically significant, present at birth, and persists in postnatal life unless or until repaired.
- Rate of minor congenital malformations [ Time Frame: Approximately 2 years (1 year post-delivery) ]Defined as a defect that occurs infrequently in the population but that has neither cosmetic nor functional significance to the child and is identified in the infant up to 1 year of age.
- Rate of spontaneous abortion [ Time Frame: Up to 9 months ]Defined as non-deliberate embryonic or fetal death that occurs prior to 20 weeks gestation post-last menstrual period.
- Rate of elective or therapeutic pregnancy termination [ Time Frame: Up to 9 months ]Rate of elective or therapeutic pregnancy termination.
- Rate of stillbirth [ Time Frame: Up to 9 months ]Defined as non-deliberate fetal death that occurs at or after 20 weeks gestation but prior to delivery.
- Rate of preterm birth [ Time Frame: Up to 9 months ]Defined as live birth prior to 37 weeks gestation as counted from last menstrual period or based on ultrasound used for conception dating.
- Rate of maternal placental issues [ Time Frame: Up to 9 months ]Rate of maternal placental issues, including placenta previa and placental abruption.
- Rate of small for gestation age infants [ Time Frame: Up to 9 months ]Defined as birth size (weight, length, or head circumference) less than or equal to the 10th percentile for sex and gestational age using National Center for Health Statistics (NCHS) pediatric growth curves for full-term infants. Prenatal growth curves specific to preterm infants will be used for premature infants.
- Rate of postnatal growth deficiency or failure to thrive [ Time Frame: Approximately 2 years (1 year post-delivery) ]Rate of postnatal growth deficiency or failure to thrive as diagnosed by his/her treating physician using criteria such as a significant weight or weight-for-height deceleration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04464187
|Contact: Susan Goon||+1 (862) email@example.com|
|United States, North Carolina|
|Iqvia /Id# 240918||Recruiting|
|Durham, North Carolina, United States, 27703-8426|
|Study Director:||ABBVIE INC.||AbbVie|